Current Clinical Trials
To find more information on a specific trial, click on the trial name below:
Individuals who have recovered from COVID-19 develop proteins called antibodies in the part of their blood called plasma. Because these antibodies can block COVID-19 infection, the U.S Food and Administration has authorized the transfusion of plasma isolated from COVID-19 convalescent donors to treat severely ill individuals, and help them fight the disease.
The purpose of this study is to assess the safety of CYNK-001 and to test the effects of CYNK-001 on people with COVID-19. The study plans to find out the best dose of CYNK-001 and to find out if CYNK-001 improves or worsens the disease.
The purpose of this study is to test a possible new cell therapy treatment called Descartes-08 in patients with Generalized Myasthenia Gravis (GMG). This study will test the safety, tolerability, and feasibility of Descartes-08.
Seeking participants for a research study who have locally advanced or metastatic solid tumors, specifically: melanoma, bladder cancer, colorectal cancer, ovarian cancer, breast cancer, or prostate cancer where the disease has progressed after at least one available standard therapy, and for whom no additional therapies are available
The purpose of this study is to confirm how well Cx601 works compared to a placebo, and how safe and tolerable Cx601 is compared to placebo for the treatment of complex perianal fistula(s) in subjects with Crohn’s disease.
The purpose of this study is to test a possible new treatment called VC‐02 for Type I Diabetes. This study will test whether the VC‐02 Combination Product can be implanted and maintained with safety, tolerability, and effectiveness.